Status:
COMPLETED
Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Hepatectomy is still the most important treatment for HCC.High recurrence rate mostly influence it's prognosis, especially for the patient with tumor \>5cm, multiple tumor and who cannot accept R0 res...
Detailed Description
150 HCC patients with tumor \>5cm, multiple tumor and who cannot accept R0 resection will be randomized divided into 3 groups. Group A (50 cases) will be implanted 600mg sustained released 5-FU into l...
Eligibility Criteria
Inclusion
- tumor \>5cm;
- multiple tumor located in one liver lobe;
- margin of tumor is not clear;
- cutting edge to tumor \<1cm;
- portal vein branch invasion;
- without extra-liver metastasis;
- patient's liver function and condition is able to accept hepatectomy.
Exclusion
- single tumor \<=5cm;
- multiple tumor located more than in one liver lobe;
- margin of tumor is clear;
- cutting edge to tumor \>=1cm;
- portal vein stem invasion
- extra-liver metastasis;
- patient's liver function and condition cannot accept hepatectomy.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00817895
Start Date
December 1 2008
End Date
December 1 2010
Last Update
March 31 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eastern Hepatobiliary Surgery Hospital
Shanghai, Shanghai Municipality, China, 200438